Technical Analysis for KNTE - Kinnate Biopharma Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | N/A | N/A | Flat |
| Historical KNTE trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Bearish Engulfing | Bearish | 0.00% | |
| Fell Below 20 DMA | Bearish | 0.00% | |
| Multiple of Ten Bearish | Other | 0.00% | |
| Narrow Range Bar | Range Contraction | -4.25% | |
| NR7 | Range Contraction | -4.25% | |
| Up 3 Days in a Row | Strength | -4.25% | |
| Up 4 Days in a Row | Strength | -4.25% | |
| Up 5 Days in a Row | Strength | -4.25% | |
| Narrow Range Bar | Range Contraction | -3.53% | |
| Inside Day | Range Contraction | -3.53% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time | |
|---|---|---|
| 20 DMA Support | 2 days ago | |
| 10 DMA Support | 2 days ago | |
| Fell Below 20 DMA | 2 days ago | |
| 60 Minute Opening Range Breakdown | 2 days ago | |
| Down 3% | 2 days ago |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: ???
Kinnate Biopharma Inc., a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors for treating genomically defined cancers. The company's lead product candidate is KIN002787, which is a rapidly accelerated fibrosarcoma inhibitor that is in preclinical stage for the treatment of patients with lung cancer, melanoma, and other solid tumors. Its other products in preclinical stage include KIN003, which are small-molecule kinase inhibitors that target cancer-associated alterations in fibroblast growth factor receptors (FGFR)2 and FGFR3 genes; and small molecule research programs, including a Cyclin-Dependent Kinase 12 inhibitor in its KIN004 program. Kinnate Biopharma Inc. was founded in 2018 and is headquartered in San Diego, California.
Sector: Healthcare
Industry: Biotechnology
Keywords: Cancer Solid Tumors Melanoma Sarcoma Lung Cancer Fibroblast Growth Factor Fibroblast Growth Factor Receptor
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Cancer Solid Tumors Melanoma Sarcoma Lung Cancer Fibroblast Growth Factor Fibroblast Growth Factor Receptor
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 48.75 |
| 52 Week Low | 34.14 |
| Average Volume | 273,974 |
| 200-Day Moving Average | 0.00 |
| 50-Day Moving Average | 0.00 |
| 20-Day Moving Average | 38.38 |
| 10-Day Moving Average | 38.12 |
| Average True Range | 2.91 |
| ADX | 12.41 |
| +DI | 16.69 |
| -DI | 20.20 |
| Chandelier Exit (Long, 3 ATRs ) | 33.68 |
| Chandelier Exit (Short, 3 ATRs ) | 42.86 |
| Upper Bollinger Band | 40.85 |
| Lower Bollinger Band | 35.91 |
| Percent B (%b) | 0.48 |
| BandWidth | 12.88 |
| MACD Line | -0.71 |
| MACD Signal Line | -0.96 |
| MACD Histogram | 0.2402 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 41.31 | ||||
| Resistance 3 (R3) | 41.56 | 40.80 | 40.81 | ||
| Resistance 2 (R2) | 40.80 | 40.04 | 40.68 | 40.64 | |
| Resistance 1 (R1) | 39.55 | 39.56 | 39.18 | 39.30 | 40.47 |
| Pivot Point | 38.80 | 38.80 | 38.61 | 38.67 | 38.80 |
| Support 1 (S1) | 37.55 | 38.03 | 37.17 | 37.30 | 36.13 |
| Support 2 (S2) | 36.79 | 37.56 | 36.67 | 35.96 | |
| Support 3 (S3) | 35.54 | 36.79 | 35.79 | ||
| Support 4 (S4) | 35.29 |
